Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Clinical Trial Samples & Registry Study Purchase by Quarter
Clinical Trial Samples & Registry Study Purchase Obligations ($M) ($M)
Natera Clinical Trial Samples & Registry Study Purchase: $1.30M in Q2 2026, down 78.3% from a year earlier.
Latest, Q2 2026
1.30
Period ended Jun 30, 2026
Change on a year earlier
-78.3%
6 in Q2 2025
History
7 quarters
Since Q4 2024
Sources
7
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Reported in Form 10-K/10-Q Note — Commitments & Contingencies (XBRL).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Clinical Trial Samples & Registry Study Purchase Obligations ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1.30 | -78.3% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 1.30 | -78.3% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 1.30 | -90.0% | Form 10-K (2026-02-27) ↗ |
| Q3 2025 | Sep 30, 2025 | 6 | – | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 6 | – | Form 10-Q (2025-08-08) ↗ |
| Q1 2025 | Mar 31, 2025 | 6 | – | Form 10-Q (2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 13 | – | Form 10-K (2025-02-28) ↗ |
Cite this data
StockData. (2026). Natera Clinical Trial Samples & Registry Study Purchase ($M), quarterly Q4 2024–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/purchase-oblig-clinical-samples
See every metric in the Natera KPI table. Data updated Nov 2, 2026.